Microbiome Therapeutics (MBT) was founded in 2009 as NuMe Health by John Elstrott, Chairman; Dale Pfost, CEO and Mark Heiman, CSO. We were pioneers in our early focus on the emerging science of the microbiome and our involvement and knowledge base have expanded over the past seven years, with our own Dr. Mark Heiman becoming an acknowledged leader in the field. The company has undertaken two successful clinical trials with its lead GI microbiome modulator and is preparing to launch its first product, a dietary supplement, named BiomeBliss™.